Metabolomic fingerprint of coronary blood in STEMI patients depends on the ischemic time and inflammatory state

Deidda, Martino; Piras, Cristina; Binaghi, G; Congia, Damiana; Pani, A; Boi, Alberto; Sanna, Francesco; Rossi, Angélica; Loi, Bruno; Dessalvi, Christian Cadeddu; Atzori, Luigi; Porcu, Maurizio; Mercuro, Giuseppe

doi:10.1038/s41598-018-36415-y

Cited by 12 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A handful of metabolomic studies have been conducted in patients presenting with STEMI 23–25 . But none of these studies have investigated the time-effect changes in plasma metabolome before and after PPCI which is crucial to provide insights into the altered metabolic pathways with clinical relevance during I/R injury.…”

Section: Discussionmentioning

confidence: 99%

Metabolomic characterization of myocardial ischemia-reperfusion injury in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention

Surendran

Aliani

Ravandi

2019

Sci Rep

View full text Add to dashboard Cite

Aim: The aim of the study was to discover the metabolomic changes in plasma that occur during human Ischemia-Reperfusion (I/R) injury and to evaluate the diagnostic utility of plasma metabolomic biomarkers for determination of myocardial injury. Deciphering the details of plasma metabolome in ST-segment elevation myocardial infarction (STEMI) patients before and after primary percutaneous coronary interventions (PPCI) would allow for better understanding of the mechanisms involved during acute myocardial ischemia and reperfusion in humans. We performed a detailed non-targeted metabolomic analysis of plasma from 27 STEMI patients who had undergone PPCI in the first 48 hrs employing a LC-MS approach. Plasma metabolome at ischemic condition was compared to multiple time points after PPCI which allowed us to focus on changes in the reperfusion phase. Classification of the differential metabolites based on chemical taxonomy identified a major role for lipids and lipid-derived molecules. Biochemical pathway analysis identified valine, leucine and isoleucine biosynthesis, vitamin B6 metabolism and glutathione metabolism as the most significant metabolic pathways representing early response to I/R injury. We also identified phenyl alanine, tyrosine, linoleic acid and glycerophospholipid metabolism as the most significant pathways representing late response to I/R injury. A panel of three metabolites pentadecanoic acid, linoleoyl carnitine and 1-linoleoylglycerophosphocholine was discovered to have diagnostic value in determining the extent of I/R injury based on cardiac biomarkers. Using a non-targeted LC-MS approach, we have successfully generated the most comprehensive data to date on significant changes in the plasma metabolome in STEMI patients who had undergone PPCI in the first 48 hrs showing that lipid metabolites represent the largest cohort of molecules undergoing significant change.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolomic characterization of myocardial ischemia-reperfusion injury in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention

Surendran

Aliani

Ravandi

2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…An early metabolomics study showed that 1H-NMR spectroscopy could correctly diagnose the presence of CAD and assess its severity [40]. Other applications of NMR-based metabolic profiling in ACS mainly include analysis of both urine [36] and serum [33,34] metabolites for unstable angina pectoris disease, investigating the serum metabolic characteristics of acute myocardial infarction (AMI) patients in comparison with those of chest pain controls [41], and deciphering the metabolomic fingerprint of coronary blood in STEMI patients [42]. Abbreviations: STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; NSTEACS, non-ST-elevation ACS; NOCAD, nonobstructive coronary artery disease; AMI, acute myocardial infarction; AHF, acute heart failure; MI, myocardial infarction; SA, stable angina pectoris; UA, unstable angina pectoris; PCI, percutaneous coronary intervention; ACS, acute coronary syndromes; CAD, coronary artery disease; HC, healthy control; LC/MS, liquid chromatography/mass spectrometry; GC/MS, gas chromatography/mass spectrometry; H-NMR, proton nuclear magnetic resonance; SPME, solid-phase microextraction; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; TCA, tricarboxylic acid cycle.…”

Section: Nmr Spectroscopymentioning

confidence: 99%

Defining Acute Coronary Syndrome through Metabolomics

et al. 2021

View full text Add to dashboard Cite

As an emerging platform technology, metabolomics offers new insights into the pathomechanisms associated with complex disease conditions, including cardiovascular diseases. It also facilitates assessing the risk of developing the disease before its clinical manifestation. For this reason, metabolomics is of growing interest for understanding the pathogenesis of acute coronary syndromes (ACS), finding new biomarkers of ACS, and its associated risk management. Metabolomics-based studies in ACS have already demonstrated immense potential for biomarker discovery and mechanistic insights by identifying metabolomic signatures (e.g., branched-chain amino acids, acylcarnitines, lysophosphatidylcholines) associated with disease progression. Herein, we discuss the various metabolomics approaches and the challenges involved in metabolic profiling, focusing on ACS. Special attention has been paid to the clinical studies of metabolomics and lipidomics in ACS, with an emphasis on ischemia/reperfusion injury.

show abstract

“…Metabolomics is a powerful analytical tool used for the identification of low molecular weight molecules, able to capture disease-specific metabolic signatures as possible biomarkers. In the last 10 years, metabolomics has been applied widely and successfully in various fields of medicine for the study and discrimination of various pathologies such as cardiovascular 29,30 and neurodegenerative and psychiatric diseases 31,32 , as well as cancer 33 . To date, the pathogenesis of FM and specifically of IEI-EMF is completely unknown.…”

mentioning

confidence: 99%

Metabolomics and psychological features in fibromyalgia and electromagnetic sensitivity

Piras

Conte

Pibiri

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Fibromyalgia (FM) as Fibromyalgia and Electromagnetic Sensitivity (IEI-EMF) are a chronic and systemic syndrome. The main symptom is represented by strong and widespread pain in the musculoskeletal system. The exact causes that lead to the development of FM and IEI-EMF are still unknown. Interestingly, the proximity to electrical and electromagnetic devices seems to trigger and/or amplify the symptoms. We investigated the blood plasma metabolome in IEI-EMF and healthy subjects using 1H NMR spectroscopy coupled with multivariate statistical analysis. All the individuals were subjected to tests for the evaluation of psychological and physical features. No significant differences between IEI-EMF and controls relative to personality aspects, Locus of Control, and anxiety were found. Multivariate statistical analysis on the metabolites identified by NMR analysis allowed the identification of a distinct metabolic profile between IEI-EMF and healthy subjects. IEI-EMF were characterized by higher levels of glycine and pyroglutamate, and lower levels of 2-hydroxyisocaproate, choline, glutamine, and isoleucine compared to healthy subjects. These metabolites are involved in several metabolic pathways mainly related to oxidative stress defense, pain mechanisms, and muscle metabolism. The results here obtained highlight possible physiopathological mechanisms in IEI-EMF patients to be better defined.

show abstract

Metabolomic fingerprint of coronary blood in STEMI patients depends on the ischemic time and inflammatory state

Cited by 12 publications

References 34 publications

Metabolomic characterization of myocardial ischemia-reperfusion injury in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention

Metabolomic characterization of myocardial ischemia-reperfusion injury in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention

Defining Acute Coronary Syndrome through Metabolomics

Metabolomics and psychological features in fibromyalgia and electromagnetic sensitivity

Contact Info

Product

Resources

About